不同剂量替罗非班联合冠脉介入术治疗非ST段抬高型急性冠脉综合征患者的临床疗效及安全性
打开文本图片集
[摘要] 目的 该次主要对不同剂量替罗非班与冠脉介入术（PCI）治疗非ST段抬高型急性冠脉综合征（NST-ACS）患者的效果与及安全性进行分析。方法 方便选取该院2014年10月”2016年10月收治并已确诊的（NST-ACS）患者150例，根据所有患者入院治疗差异平均分为3组，即A组（常规治疗+PCI），B组（在A组治疗基础上给予全量替罗非班），C组（在A组治疗前提下给予半量替罗非班）。对比3组疗效。结果 B组治疗的总疗效100.00%与C组的96.00%高于A组的86.00%，差异有统计学意义（P<0.05），有可比性；但B、C两组对比差异无统计学意义（P>0.05）。结论 NST-ACS患者经半量替罗非班结合冠脉介入术治疗的临床效果确切，不仅可提高治疗的效果，还能有效降低心血管事件的发生机率，值得推广。
[关键词] 冠脉介入术；非ST段抬高型急性冠脉综合征；疗效；安全性
[中图分类号] R541.4 [文献标识码] A [文章编号] 1674-0742（2017）02（b）-0120-03
[Abstract] Objective To analyze the clinical curative effect and safety of different doses of tirofiban and percutaneous coronary intervention in treatment of NEST-ACS. Methods Convenient selection 150 cases of patients with NEST-ACS admitted and treated in our hospital from October 2014 to October 2016 were selected and divided into three groups with 50 cases in each， the group A were treated with routine method and PCI， the group B were treated with full-dose tirofiban on the basis of the group A， the group C wre treated with half-dose tirofiban on the basis of the group A， and the curative effect of the three groups was compared. Results The total curative effect in the group B and the group C was higher than that in the group A（100.00%， 96.00% vs 86.00%）， and the difference had statistical significance（P<0.05）， and the difference between the grou...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
